104 related articles for article (PubMed ID: 14561850)
1. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 2. Improved renal function as assessed by dynamic contrast-enhanced magnetic resonance imaging.
Lenhard SC; Nerurkar SS; Schaeffer TR; Mirabile RC; Boyce RW; Adams DF; Jucker BM; Willette RN
J Pharmacol Exp Ther; 2003 Dec; 307(3):939-46. PubMed ID: 14561850
[TBL] [Abstract][Full Text] [Related]
2. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension.
Ju H; Behm DJ; Nerurkar S; Eybye ME; Haimbach RE; Olzinski AR; Douglas SA; Willette RN
J Pharmacol Exp Ther; 2003 Dec; 307(3):932-8. PubMed ID: 14561851
[TBL] [Abstract][Full Text] [Related]
3. Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection.
Olzinski AR; McCafferty TA; Zhao SQ; Behm DJ; Eybye ME; Maniscalco K; Bentley R; Frazier KS; Milliner CM; Mirabile RC; Coatney RW; Willette RN
Cardiovasc Res; 2005 Apr; 66(1):170-8. PubMed ID: 15769460
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.
Willette RN; Eybye ME; Olzinski AR; Behm DJ; Aiyar N; Maniscalco K; Bentley RG; Coatney RW; Zhao S; Westfall TD; Doe CP
J Pharmacol Exp Ther; 2009 Sep; 330(3):964-70. PubMed ID: 19556450
[TBL] [Abstract][Full Text] [Related]
5. Effects of p38 mitogen-activated protein kinase inhibition on blood pressure, renal hemodynamics, and renal vascular reactivity in normal and diabetic rats.
Komers R; Schutzer W; Xue H; Oyama TT; Lindsley JN; Anderson S
Transl Res; 2007 Dec; 150(6):343-9. PubMed ID: 18022596
[TBL] [Abstract][Full Text] [Related]
6. Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.
Bao W; Behm DJ; Nerurkar SS; Ao Z; Bentley R; Mirabile RC; Johns DG; Woods TN; Doe CP; Coatney RW; Ohlstein JF; Douglas SA; Willette RN; Yue TL
J Cardiovasc Pharmacol; 2007 Jun; 49(6):362-8. PubMed ID: 17577100
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats.
Wang J; Huang H; Liu P; Tang F; Qin J; Huang W; Chen F; Guo F; Liu W; Yang B
Eur J Pharmacol; 2006 Dec; 553(1-3):297-303. PubMed ID: 17074319
[TBL] [Abstract][Full Text] [Related]
8. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction.
Behr TM; Nerurkar SS; Nelson AH; Coatney RW; Woods TN; Sulpizio A; Chandra S; Brooks DP; Kumar S; Lee JC; Ohlstein EH; Angermann CE; Adams JL; Sisko J; Sackner-Bernstein JD; Willette RN
Circulation; 2001 Sep; 104(11):1292-8. PubMed ID: 11551882
[TBL] [Abstract][Full Text] [Related]
9. Activation of p38 mitogen-activated protein kinase abolishes insulin-mediated myocardial protection against ischemia-reperfusion injury.
Chai W; Wu Y; Li G; Cao W; Yang Z; Liu Z
Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E183-9. PubMed ID: 18003719
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent.
Widder J; Behr T; Fraccarollo D; Hu K; Galuppo P; Tas P; Angermann CE; Ertl G; Bauersachs J
Cardiovasc Res; 2004 Jul; 63(1):161-7. PubMed ID: 15194473
[TBL] [Abstract][Full Text] [Related]
11. Chronic treatment of DA-8159, a new phosphodiesterase type V inhibitor, attenuates endothelial dysfunction in stroke-prone spontaneously hypertensive rat.
Choi SM; Kim JE; Kang KK
Life Sci; 2006 Feb; 78(11):1211-6. PubMed ID: 16214180
[TBL] [Abstract][Full Text] [Related]
12. [Induction mechanism of shock: applying the etiology in judgment of the cause of death in forensic practice].
Tanaka N
Nihon Hoigaku Zasshi; 2004 Sep; 58(2):130-40. PubMed ID: 15526767
[TBL] [Abstract][Full Text] [Related]
13. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.
Legos JJ; Lenhard SC; Haimbach RE; Schaeffer TR; Bentley RG; McVey MJ; Chandra S; Irving EA; Andrew A Parsons ; Barone FC
Exp Neurol; 2008 Jul; 212(1):53-62. PubMed ID: 18462720
[TBL] [Abstract][Full Text] [Related]
14. P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1.
Nerurkar SS; Olzinski AR; Frazier KS; Mirabile RC; O'Brien SP; Jing J; Rajagopalan D; Yue TL; Willette RN
Biomarkers; 2007; 12(1):87-112. PubMed ID: 17438656
[TBL] [Abstract][Full Text] [Related]
15. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Barone FC; Coatney RW; Chandra S; Sarkar SK; Nelson AH; Contino LC; Brooks DP; Campbell WG; Ohlstein EH; Willette RN
Cardiovasc Res; 2001 Jun; 50(3):525-37. PubMed ID: 11376628
[TBL] [Abstract][Full Text] [Related]
16. Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.
Kompa AR; See F; Lewis DA; Adrahtas A; Cantwell DM; Wang BH; Krum H
J Pharmacol Exp Ther; 2008 Jun; 325(3):741-50. PubMed ID: 18334667
[TBL] [Abstract][Full Text] [Related]
17. Effects of uninephrectomy on renal structural properties in spontaneously hypertensive rats.
Kinuno H; Tomoda F; Koike T; Takata M; Inoue H
Clin Exp Pharmacol Physiol; 2005 Mar; 32(3):173-8. PubMed ID: 15743399
[TBL] [Abstract][Full Text] [Related]
18. [Effects of lovastatin on renal function and expression of phosphorylating-p38 mitogen-activated protein kinase in experimental diabetic nephropathy in rats].
Wang LH; Duan HJ; Shi YH; Liu QJ; He N; Liu SX
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 Dec; 16(12):734-7. PubMed ID: 15585148
[TBL] [Abstract][Full Text] [Related]
19. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
[TBL] [Abstract][Full Text] [Related]
20. N-Acetylcysteine improves renal dysfunction, ameliorates kidney damage and decreases blood pressure in salt-sensitive hypertension.
Tian N; Rose RA; Jordan S; Dwyer TM; Hughson MD; Manning RD
J Hypertens; 2006 Nov; 24(11):2263-70. PubMed ID: 17053549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
